Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Neuroblastoma 2Pheochromocytoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

3-Iodobenzylguanidine 8anlotinib 4Temozolomide 4lutetium Lu 177 dotatate 3Phenoxybenzamine 3Everolimus 3pegfilgrastim 2cabozantinib 2Granulocyte Colony-Stimulating Factor 2Doxazosin 2Dexmedetomidine 2Capecitabine 2Adrenalectomy 23-fluorobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2veliparib 1vatalanib 1vandetanib 1temsirolimus 1pentetreotide 1penpulimab 1pembrolizumab 1olaparib 1lenvatinib 1lanreotide 1gallium Ga 68 dotatate 1fluorodopa F 18 1fludarabine phosphate 1belzutifan 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pheochromocytoma × Potassium Iodide × Clear all
NCT03649438 2024-12-11

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

University of Texas Southwestern Medical Center

No longer available
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡